Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Frailty Predicts Incident Osteoporotic Fractures in Veterans with Rheumatoid Arthritis.

Arthritis care & research·2026

Same author

Inferring Rheumatoid Arthritis Disease Activity Status From the Electronic Health Records Across Health Systems.

Arthritis & rheumatology (Hoboken, N.J.)·2026

Same author

Associations of Rheumatoid Arthritis Disease Activity With Frailty Over Five Years of Follow-up.

Arthritis care & research·2026

Same author

Immune Checkpoint Inhibitor-Related Myositis and Associated Triad Overlap Syndrome.

Arthritis care & research·2026

Same author

Performance of the Predicting Risk of Cardiovascular Disease Events Calculator in Rheumatoid Arthritis.

Arthritis & rheumatology (Hoboken, N.J.)·2026

Same author

Heterogeneity in the association of genetic risk for RA and resultant RA phenotypes.

Rheumatology (Oxford, England)·2026

Search research articles

Related Experiment Video

Updated: May 1, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 3, 2013

Biomarkers for benign prostatic hyperplasia progression.

Grant W Cannon¹, Robert H Getzenberg

¹The Brady Urological Institute, Johns Hopkins Hospital, Marburg 121, 600 North Wolfe Street, Baltimore, MD 21287, USA.

Current Urology Reports

|September 4, 2008

Summary

This summary is machine-generated.

No molecular markers currently exist for benign prostatic hyperplasia (BPH) or its progression. Ongoing research aims to identify and validate biomarkers for improved patient stratification and personalized treatment strategies.

More Related Videos

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

Related Experiment Videos

Last Updated: May 1, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 3, 2013

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

Area of Science:

Urology
Molecular Biology
Biomarker Discovery

Background:

Benign prostatic hyperplasia (BPH) affects nearly all aging men.
Current diagnostic and prognostic tools for BPH lack molecular specificity.
There is a critical need for biomarkers to predict BPH progression and guide treatment.

Purpose of the Study:

To highlight the unmet need for molecular markers in benign prostatic hyperplasia.
To discuss the potential of molecular biomarkers for patient stratification and predicting disease progression.
To review the current landscape and future prospects of BPH biomarker research.

Main Methods:

Literature review of current research on benign prostatic hyperplasia biomarkers.
Analysis of the potential clinical utility of identified molecular markers.
Discussion of ongoing research and validation efforts for BPH biomarkers.

Main Results:

No molecular markers are currently approved for clinical use in BPH.
Several molecular biomarkers show promise for stratifying patients and predicting disease progression.
Research is actively progressing to discover and validate novel biomarkers.

Conclusions:

The development of validated molecular markers for BPH is crucial for personalized medicine.
Future research holds promise for improved diagnosis and management of benign prostatic hyperplasia.
Biomarker optimization and validation are key steps towards clinical implementation.